ArticleRheumatology (Oxford, England)2025

Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis.

Nina R Goldman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.